Back to Agenda
SESSION 2
Session Chair(s)
Tomas Salmonson, DrMed, PHD
, Critical Path Institute, Netherlands
This session will talk about how the M2 expert group will impact on drug development and on other ICH guidelines. Translation of standards to real impact for drug discovery and impacts on public health. This session will focus on the changes that S1, S5, and S11 will introduce.
Speaker(s)
Joris Kampmeijer
Information Processing Department, Medicines Evaluation Board , Netherlands
M2 Electronic Standards
Jan Willem van der Laan, PHD
Senior Assessor Pharmacology and Toxicology , Retired From Medicines Evaluation Board, Netherlands
S Series: Changing paradigms in non-clinical drug development
Have an account?
